Get to know our clinical trials
A Phase II, open-label, single-arm, multicenter study of Ciltacabtagene Autoleucel in high-risk quiescent multiple myeloma
THE AIM OF THIS STUDY IS TO INVESTIGATE THE SAFETY AND EFFICACY OF THE DARA-VRD REGIMEN FOLLOWED BY CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A CAR-T THERAPY, IN PATIENTS DIAGNOSED WITH HIGH-RISK MMQ.
Technical Summary
- A PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF CILTACABTAGENE AUTOLEUCEL IN HIGH-RISK QUIESCENT MULTIPLE MYELOMA
- Code EudraCT: 2023-510560-12
- Protocol number: GEM-CAR-HIRISMM
- Promoter: Fundación Pethema
- Molecule/Drug: Ciltacabtagén Autoleucel
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.